Ro Body

At a glance

How the program is structured

A membership-based clinical program with several current brand-name oral and injectable options, insurance navigation, cash fulfillment, and ongoing messaging. The membership and medication are separate charges.

GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.

Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.

Service configuration

These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.

Provider type

Telehealth program

Medicine context

Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)

Formats reviewed

Injection · Oral medicine

Funding routes

Private pay · Insurance support

Service features

Clinician support · Switching pathway · Home delivery

Access check

Confirm current state access

Evidence status

Primary sources reviewed

Research depth

2 cited sources · 4 medicine rows · 4 open checks

Recurring cost breakdown

• $39 introductory first month was displayed at review.
• Ongoing membership was displayed from $74/month with annual prepayment or $149 month-to-month.
• Medication is separate. Cash and insurance pathways have different product prices and fulfillment routes.
• Membership includes provider messaging, dose and side-effect support, tracking, and coaching features.

Medication and formulation matrix

Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.

State-by-state availability

• Multi-state US access is advertised; medication, clinician, and pharmacy availability can vary by state.
• The public program page does not provide one durable all-products-by-state matrix.

Clinician access and follow-up cadence

• Initial online intake and clinician evaluation precede prescribing.
• Regular check-ins and 24/7 care-team messaging are advertised; individual visit timing is care-plan dependent.
• Clinical support includes titration and side-effect management.

Pharmacy and fulfillment

• Cash-pay medication is advertised for home delivery.
• Insurance-covered prescriptions may be sent to a local pharmacy for pickup.
• The exact dispensing partner depends on the product and route and should be visible before fulfillment.

Insurance and prior authorization

• Insurance concierge support includes benefit review and prior-authorization submission.
• Ro says the authorization process commonly takes two to three weeks.
• A denial does not make a cash alternative equivalent in price; compare the new total before switching routes.

Cancellation, refund, and commitment

• Month-to-month and prepaid membership structures have different financial commitments.
• Review the current cancellation and refund page before annual prepayment; medication already processed or dispensed may be treated separately.

Labs, monitoring, and dose management

• Lab requirements depend on medical history and chosen treatment and were not presented as a universal included benefit.
• Ongoing weight, tolerance, and dose tracking are part of the advertised program.

Maintenance and switching

• Ro says people already receiving treatment may be able to continue after clinical intake.
• Continuation at an identical dose, brand, or refill date remains a clinical and coverage decision; upload prescription history before canceling current care.

Program snapshot

What the advertised program may include

• Clinician evaluation
• Ongoing provider messaging
• Insurance concierge for eligible paths
• Program tools and tracking

Useful comparison signals

Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.

• Starting care and comparing first-provider requirements
• Switching providers or continuing an established treatment
• Comparing lower-cost access routes and recurring totals
• Ongoing clinician access
• Simplified intake and fulfillment

Open evidence gaps

These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.

• Single state-by-product availability table
• Named pharmacy for each cash product
• Universal lab schedule
• Net medication cost before benefit verification

Questions to ask before paying

1. What is the ordinary recurring total after any introductory period?
2. Does that total include clinician care, medication, supplies, labs, and shipping?
3. Which clinician group and dispensing pharmacy will be responsible for my care?
4. What happens to billing if I am not prescribed the advertised treatment?
5. What records and timing do you require if I am switching from another provider?

Source ledger

Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.